|
【结 构 式】 
|
【药物名称】SMA-41 【化学名称】N-(3-Methylphenyl)-6-(3-methyltriazen-1-yl)quinazolin-4-amine 【CA登记号】 【 分 子 式 】C16H16N6 【 分 子 量 】292.34612 |
【开发单位】McGill University (Originator) 【药理作用】ONCOLYTIC DRUGS, DNA-Damaging Drugs, EGFR (erbB1) Inhibitors, Inhibitors of Signal Transduction Pathways |
合成路线1
Arylamine (I) is converted into the corresponding methyltriazene (II) by formation of the corresponding diazonium salt with NaNO2 in HCl/H2O, followed by reaction with methylamine. Finally, the target compound is obtained by coupling of (II) with the corresponding amine in refluxing isopropanol.
| 【1】 Vaughan, K.; et al.; Studies of the model of action of antitumor triazenes and triazines. 6. 1-Ayl-3-(hydroxymethyl)-3-methyltriazenes: Synthesis, chemistry, and antitumor properties. J Med Chem 1984, 27, 3, 357. |
| 【2】 Rewcastle, G.W.; et al.; Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth f. J Med Chem 1995, 38, 18, 3482. |
Extended Information